Please check your internet connection and try again.
# Ecospirin (Aspirin, Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of aspirin, a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. The enteric coating delays absorption until it reaches the small intestine, which may reduce gastric irritation.
## Primary Indications
* **Cardiovascular Risk Reduction:** Primary and secondary prevention of cardiovascular events (e.g., myocardial infarction, stroke) in patients with established cardiovascular disease, diabetes mellitus, or multiple cardiovascular risk factors.
* **Analgesia and Antipyresis:** Mild to moderate pain and fever (less common indication for this formulation).
* **Anti-inflammatory:** Inflammatory conditions such as rheumatoid arthritis (less common indication for this formulation).
## Adult Dosing
* **Cardiovascular Risk Reduction:**
* **Primary Prevention:** Typically 75-162 mg once daily. Decision should be individualized based on risk factors and bleeding risk.
* **Secondary Prevention:** Typically 75-325 mg once daily. Loading doses may be used in acute settings (e.g., acute coronary syndrome).
* **Analgesia/Antipyresis:** 325-650 mg every 4 hours as needed. Maximum dose generally 4000 mg/day.
* **Anti-inflammatory:** 325-650 mg every 4-6 hours. Higher doses may be required, up to 3.6-5.4 g/day in divided doses, under strict medical supervision for inflammatory conditions.
## Pediatric Dosing
Aspirin is generally **contraindicated** in children and adolescents for viral infections due to the risk of Reye's syndrome. Specific pediatric dosing for other indications is not routinely established for this formulation and should be guided by specialist consultation and available pediatric studies.
## Dose Adjustments
No specific dose adjustments are typically required for renal or hepatic impairment, but caution is advised, especially in severe impairment due to potential for accumulation and toxicity.
## Contraindications
* Known hypersensitivity to aspirin, other salicylates, or NSAIDs.
* Asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.
* Active gastrointestinal bleeding or other significant active bleeding.
* History of gastrointestinal perforation or ulceration.
* Severe hepatic impairment.
* Severe renal impairment (CrCl < 30 mL/min).
* Children and adolescents with viral infections (risk of Reye's syndrome).
* Third trimester of pregnancy.
## Adverse Effects
Common: Gastrointestinal upset, dyspepsia, nausea, heartburn.
Serious: Gastrointestinal bleeding, ulceration, perforation; hypersensitivity reactions including bronchospasm and anaphylaxis; tinnitus; Reye's syndrome (in children/adolescents with viral infections); increased bleeding risk.
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs and COX-2 Inhibitors:** Increased risk of gastrointestinal toxicity and bleeding.
* **Corticosteroids:** Increased risk of gastrointestinal ulceration and bleeding.
* **SSRIs and SNRIs:** Increased risk of bleeding, particularly gastrointestinal bleeding.
* **Antihypertensives (e.g., ACE inhibitors, ARBs, diuretics):** May reduce antihypertensive efficacy and increase risk of renal impairment.
* **Methotrexate:** Aspirin may increase methotrexate toxicity.
* **Uricosuric agents (e.g., probenecid):** May reduce efficacy of uricosuric agents.
## Monitoring
* Signs and symptoms of gastrointestinal bleeding (melena, hematemesis, abdominal pain).
* Signs and symptoms of bleeding elsewhere (easy bruising, epistaxis, prolonged bleeding from cuts).
* Renal function, especially in patients with renal risk factors, dehydration, or concurrent nephrotoxic agents.
* Liver function in patients with hepatic impairment.
* Tinnitus or hearing changes, which may indicate toxicity.
## Clinical Pearls
* The enteric coating is intended to be swallowed whole and **should not** be crushed, chewed, or broken to preserve the delayed-release properties and reduce gastric irritation.
* Use the lowest effective dose for the shortest duration necessary.
* Patients with risk factors for GI bleeding (e.g., history of ulcers, advanced age, concurrent anticoagulation) may require concurrent gastroprotection (e.g., proton pump inhibitor).
* Discontinue aspirin at least 5-7 days prior to elective surgery, if feasible, after consulting with the surgical team.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant guidelines before initiating or modifying therapy. Local protocols may vary.
